Scientific Focus
Supporting the work in Quintiles Central Laboratories is a broad base of scientific knowledge. To learn how this work can propel your drug development, browse through some of our scientists’ latest contributions.
 | Flow Cytometry: A Powerful Technique for Clinical Research and Practice March 2011 |
In the pursuit of targeted therapies, drug developers are using flow cytometry to better understand disease and immunological response at the cellular level. This powerful technology gives a wealth of insight to guide development decision-making. This scientific bulletin explains how this technology is shedding light on multiple applications and Quintiles' capabilities, which include developing and validating new assays and conducting state-of-the-art assays. | |
More of our scientists' research and publications that may interest you: PI3K Biomarker Assay October 2010 An overview of the biomarker technology Quintiles uses to detect the PI3K pathway. Identifying Multiple Routes September 2010 How the PI3K pathway and biomarkers can help assess signaling and activation when developing targeted cancer therapies. As seen in Drug Discovery & Development. Outsourcing Oncology Molecular Biomarkers for Emerging Countries September 2010 How drug developers in China are taking advantage of biomarkers and companion diagnostics. Presented at CSCO. Tissue Biomarkers and Digital Pathology in Oncology Clinical Development March 2010 Our integrated model for oncology development and global network of laboratories. Integration of Molecular Biomarkers into Clinical Development March 2010 How biomarker research is driving anticancer therapy research and creation. Digital Pathology and Biomarkers Help Pave the Way to Personalized Medicine January 2010 New technologies help reduce development costs and deliver the right treatment to the right patient. As seen in PharmaAsia. Biomarker Trends in Breast Cancer Research December 2009 Summary of six studies presented at the 2009 San Antonio Breast Cancer Symposium. Changing the Face of Cancer Research August 2009 Advances in biomarker technology and digital pathology are transforming cancer therapy development. | |
